Evolution of Cardiac Assist from Intermediate In-Hospital Support of Chronic Outpatient Care
In the current era of cardiac replacement therapy, there remain two viable options; natural replacement with a donor cardiac allograft, or mechanical circulatory support with the total artificial heart or left ventricular assist device (LVAD). At present, transplantation as an option is not available in adequate numbers to appreciably reduce the numbers of patients dying yearly in the United States from end-stage heart disease. The imbalance between donors and recipients in cardiac transplantation has resulted not only from the wide application of transplantation to varied forms of end-stage heart failure, but also from more discriminating donor selection. In the future, transplant candidacy may become more selective as criteria are defined by critical analysis of current databases. Actuarial survival following heart transplant is effectively limited to 30%–40% at 10 years due to the onset of accelerated graft atherosclerosis . Unfortunately, little progress has been made in the management of immunosuppression, a factor which would reduce the incidence of this complication, which is presumed to be, at least in part, due to chronic low-grade rejection. Finally, quality of life in the heart transplant recipient may not be as excellent as once imagined in a population of very select candidates. Complications due to chronic immunosuppressive therapy, such as renal or hepatic dysfunction, osteoporosis, obesity, diabetes mellitus, and hypertension all compound the course of longterm survival.
KeywordsRight Ventricle Leave Ventricular Assist Device Cardiac Transplantation Right Ventricular Ejection Fraction Mechanical Circulatory Support
Unable to display preview. Download preview PDF.
- 3.Copeland JG, Emery RW, Levensen MM, Copeland J, McAleer MJ, Riley JE (1985) The role of mechanical support and transplantation in the treatment of patients with end-stage cardiomyopathy. Circulation 72 [Suppl I47–12Google Scholar
- 4.Griffith BP (1989) Interim use of the Jarvik-7 artificial heart: Lessons learned at Presbyterian-Unviersity Hospital of Pittsburgh. Ann Thorac Surg 47: 158166Google Scholar
- 7.Pifarre R, Sullivan HJ, Montoya A, Blakeman B, Calandra DB, Costanzo-Nordin MR, Lonchyna V, Hinkamp T, Walenga JM (1993) Bridge to transplantation with the total artificial heart: The Loyola experience. Cardiac surgery: State of the art reviews. Vol 7, No. 2, Hanley and Belfus, PhiladelphiaGoogle Scholar
- 8.Portner PM, Oyer PE, Jasswalla JS, Chen H, Miller PJ, LaForge DH, Green GF, Shumway NE (1984) A totally implantable ventricular assist device for end-stage heart disease. In: Unger F (ed) Assisted circulation 2. Springer, Berlin Heidelberg New York Tokyo, pp 115141Google Scholar
- 11.Kormos RL, Murali S, Dew MA, Armitage JM, Hardesty RL, Borovetz HS, Griffith BP (1994) Chronic mechanical circulatory support: Rehabilitation, low morbidity, and superior survival. Ann Thorac Surg 57: 51–8Google Scholar
- 12.Morita S, Kormos RL, Mandarino WA, Eishi K, Kawai A, Gasior TA, Deneault LG, Armitage JM, Hardesty RL, Griffith BP (1992) Right ventricular/arterial coupling in the patient with left ventricular assistance. Circulation 86 [Suppl 1I1: 11316–11325Google Scholar
- 14.Kawai A, Kormos, RL, Griffith BP (1993) Management of infections in mechanical circulatory support devices. Cardiac surgery: State of the art reviews. Vol 7, No. 2. Hanley and Belfus, PhiladelphiaGoogle Scholar